LLY

1,004.72

-2.73%↓

JNJ

246.41

-0.72%↓

ABBV

232.24

+0.14%↑

NVS

161.04

-2.99%↓

MRK

119.56

-1.51%↓

LLY

1,004.72

-2.73%↓

JNJ

246.41

-0.72%↓

ABBV

232.24

+0.14%↑

NVS

161.04

-2.99%↓

MRK

119.56

-1.51%↓

LLY

1,004.72

-2.73%↓

JNJ

246.41

-0.72%↓

ABBV

232.24

+0.14%↑

NVS

161.04

-2.99%↓

MRK

119.56

-1.51%↓

LLY

1,004.72

-2.73%↓

JNJ

246.41

-0.72%↓

ABBV

232.24

+0.14%↑

NVS

161.04

-2.99%↓

MRK

119.56

-1.51%↓

LLY

1,004.72

-2.73%↓

JNJ

246.41

-0.72%↓

ABBV

232.24

+0.14%↑

NVS

161.04

-2.99%↓

MRK

119.56

-1.51%↓

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

5.1 -6.42

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

5.47

Galvenie mērījumi
By Trading Economics
Ienākumi	-14M -14M
Pārdošana	-13M 6M
P/E Sektora vidējais	18.6 108.767
Peļņas marža	-238.621
Darbinieki	119
EBITDA	-13M -14M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+76.91% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	297M 945M
Iepriekšējā atvēršanas cena	11.52
Iepriekšējā slēgšanas cena	5.1

Ziņu noskaņojums

By Acuity

57%

43%

288 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. marts 23:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2026. g. 2. marts 23:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2026. g. 2. marts 23:26 UTC

Galvenie ziņu notikumi

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2026. g. 2. marts 22:41 UTC

Tirgus saruna

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2026. g. 2. marts 22:32 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. marts 22:32 UTC

Tirgus saruna

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2026. g. 2. marts 22:21 UTC

Tirgus saruna

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2026. g. 2. marts 22:11 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 2. marts 22:11 UTC

Tirgus saruna

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2026. g. 2. marts 22:10 UTC

Iegādes, apvienošanās, pārņemšana

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2026. g. 2. marts 22:06 UTC

Tirgus saruna

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2026. g. 2. marts 22:00 UTC

Tirgus saruna

Peļņas

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. marts 22:00 UTC

Tirgus saruna

Peļņas

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2026. g. 2. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Energy & Utilities Roundup: Market Talk

2026. g. 2. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 2. marts 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 2. marts 21:35 UTC

Iegādes, apvienošanās, pārņemšana

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2026. g. 2. marts 21:34 UTC

Iegādes, apvienošanās, pārņemšana

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2026. g. 2. marts 21:30 UTC

Iegādes, apvienošanās, pārņemšana

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2026. g. 2. marts 21:17 UTC

Galvenie ziņu notikumi

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2026. g. 2. marts 20:44 UTC

Peļņas

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2026. g. 2. marts 20:43 UTC

Tirgus saruna

Galvenie ziņu notikumi

Treasury Yields Rise, Dollar Strengthens After Attack on Iran -- Market Talk

2026. g. 2. marts 20:28 UTC

Peļņas

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2026. g. 2. marts 20:25 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2026. g. 2. marts 20:24 UTC

Peļņas

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2026. g. 2. marts 20:14 UTC

Iegādes, apvienošanās, pārņemšana

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2026. g. 2. marts 20:12 UTC

Galvenie ziņu notikumi

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2026. g. 2. marts 20:08 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. marts 20:08 UTC

Tirgus saruna

Galvenie ziņu notikumi

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2026. g. 2. marts 20:05 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

76.91% augšup

Prognoze 12 mēnešiem

Vidējais 9.5 USD 76.91%

Augstākais 10 USD

Zemākais 7 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

288 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.